National Comprehensive Cancer Network
May 2018 Vol 9, No 5 | May 22, 2018
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
May 2018 Vol 9, No 5 | May 22, 2018
Updated NCCN Breast Cancer Guidelines
May 2018 Vol 9, No 5 | May 22, 2018
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.
June 2016 Vol 7, No 5 | June 7, 2016
The population of patients with multiple myeloma (MM) who are eligible for therapy has been expanded to asymptomatic patients with certain features under the most recent National Comprehensive Cancer Network (NCCN) guideline (Version 3.2016).
June 2016 Vol 7, No 5 | June 7, 2016
Tyrosine kinase inhibitors (TKIs) are the mainstay of treatment for patients with EGFR mutation–positive non–small cell lung cancer (NSCLC), according to the most recent guideline on management of NSCLC issued by the National Comprehensive Cancer Network (NCCN).
October 2014 Vol 5, No 5 | October 9, 2014
The National Comprehensive Cancer Network (NCCN) provides clinical practice guidelines in oncology for all types and stages of cancer as well as areas of supportive care.
April 2012 Vol 3, No 2 | April 27, 2012
The National Comprehensive Cancer Network® (NCCN®) is a nonprofit alliance of 21 of the world’s leading cancer centers.
Results 1 - 7 of 7
